FDA
-
-
-
-
-
-
-
FDA approves Moderna's updated 2026-2027 COVID-19 vaccines
-
-
-
-
-
-
-
Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA
-
-
-
-
-
-
-
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
-
-
-
-
-
-
-
Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
Moderna (MRNA) PT Raised to $45 at Bernstein SocGen Group
-
-
-
-
-
-
-
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
-
-
-
-
-
-
-
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA)
-
332,796 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

